KLP Kapitalforvaltning AS Purchases 5,200 Shares of Danaher Corporation (NYSE:DHR)

KLP Kapitalforvaltning AS raised its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 2.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 228,751 shares of the conglomerate's stock after acquiring an additional 5,200 shares during the period. KLP Kapitalforvaltning AS's holdings in Danaher were worth $46,956,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Geode Capital Management LLC raised its position in shares of Danaher by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock valued at $3,056,996,000 after acquiring an additional 315,446 shares during the last quarter. Norges Bank bought a new stake in shares of Danaher during the 4th quarter valued at $2,130,740,000. Bank of New York Mellon Corp grew its holdings in shares of Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after buying an additional 194,466 shares during the period. Northern Trust Corp grew its holdings in shares of Danaher by 14.3% in the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock valued at $1,821,477,000 after buying an additional 992,594 shares during the period. Finally, Capital World Investors grew its holdings in shares of Danaher by 32.7% in the 4th quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after buying an additional 1,566,658 shares during the period. Institutional investors own 79.05% of the company's stock.

Insider Activity at Danaher

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president directly owned 15,179 shares in the company, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

DHR has been the subject of several research analyst reports. Wolfe Research decreased their price target on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a report on Monday, April 7th. TD Cowen boosted their price target on shares of Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a report on Wednesday, April 23rd. Bank of America decreased their price target on shares of Danaher from $265.00 to $230.00 in a report on Monday, April 14th. Royal Bank Of Canada reissued an "outperform" rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Finally, Wells Fargo & Company reduced their target price on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Stock Performance

Danaher stock traded up $5.32 during trading hours on Thursday, hitting $203.21. The company had a trading volume of 7,353,024 shares, compared to its average volume of 4,264,173. The firm has a market cap of $145.43 billion, a PE ratio of 43.24, a PEG ratio of 2.65 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70. The firm has a 50-day moving average of $195.94 and a 200 day moving average of $204.39.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.80%. The business's revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.72 EPS. On average, sell-side analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.63%. Danaher's dividend payout ratio is presently 24.85%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.